PDS Biotech Faces Nasdaq Delisting Warning After Stock Dips Below $1.00
PDSB sits 35% above its 52-week low of $0.507 on light trading volume (0.2× avg).
Summary
Nasdaq notified PDS Biotech on July 30, 2026, that its stock has fallen below the $1.00 minimum bid price, triggering a 180-day compliance period. The company may pursue a reverse stock split to avoid delisting.
Key Events · Legal and Risk Events · PDSB
-
Nasdaq Deficiency Notice Received
On July 30, 2026, PDS Biotech received a Nasdaq deficiency letter because its common stock closed below $1.00 for 30 consecutive business days, violating the minimum bid price requirement.
-
180-Day Compliance Window
The company has until January 26, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. A second 180-day period may be available if certain conditions are met.
-
Reverse Stock Split Under Consideration
Management stated it may initiate a reverse stock split to cure the deficiency, though no assurance is given that compliance will be regained.
-
Delisting Risk Looms
If compliance is not achieved by the end of the applicable period(s), the stock will be subject to delisting from The Nasdaq Capital Market, though the company could appeal.
Analysis · PDSB · Life Sciences
Nasdaq has put PDS Biotech on notice after its stock closed below $1.00 for 30 consecutive business days. The company now has until January 26, 2027, to regain compliance — likely through a reverse stock split — or face delisting. This development arrives just two months after the company had resolved a prior bid-price deficiency, and against a backdrop of heavy dilution from a recently activated $50 million ATM program and a pending shareholder vote to double authorized shares. With the stock closing at $0.6861 today, well below the $1.00 threshold, a reverse split looks increasingly probable.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.4M. The 52-week trading range was $0.51 to $1.55. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.